hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06349265, orgStudyIdInfo id: 02, briefTitle: Ultrasound-Guided 5% Dextrose Injection for Carpal Tunnel Syndrome, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-02, primaryCompletionDateStruct date: 2024-02-02, completionDateStruct date: 2024-03-02, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Kastamonu University, class: OTHER, descriptionModule briefSummary: This study was a prospective randomized double-blind clinical trial conducted at the Physical Medicine and Rehabilitation Clinic of a local research and training hospital in Turkey from October 2023 and May 2024. Patients diagnosed with CTS were classified into three groups: severe, mild, and moderate CTS, based on the results of electrophysiological tests. An ultrasound-guided 5% Dextrose in Water injection was performed. The primary outcome measurement was the Visual Analog Scale (VAS), while secondary measurements were the Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) and the Dolour Neuropathic en 4 Questions (DN4) questionnaire. The measurements were performed before the injection and at the first week, first month and third month follow-up times. The distribution of data within groups was examined using the Shapiro-Wilk test and Q-Q plots. The study also analyzed temporal changes, group differences, and intergroup changes using repeated measures ANOVA models., conditionsModule conditions: Carpal Tunnel Syndrome, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 33, type: ACTUAL, armsInterventionsModule interventions name: Carpal Tunnel Hydrodissection with %5 dextrose in water injection, outcomesModule primaryOutcomes measure: Visual Analogue Scale(VAS), secondaryOutcomes measure: Boston Carpal Tunnel Syndrome Questionnaire (BCTQ), secondaryOutcomes measure: Dolour Neuropathique en 4 Questions (DN4) questionnaire, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gamze Gül Güleç, city: Kastamonu, zip: 37150, country: Turkey, geoPoint lat: 41.37805, lon: 33.77528, hasResults: False
protocolSection identificationModule nctId: NCT06349252, orgStudyIdInfo id: LUNGTNM, briefTitle: Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: The International Association for the Study of Lung Cancer Staging Committee recently unveiled the ninth edition of TNM staging system for lung cancer. This study aims to explore survival outcomes, stage grouping, and gene mutations in N descriptors of this new classification system., conditionsModule conditions: Non-small Cell Lung Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1263, type: ESTIMATED, armsInterventionsModule interventions name: Radical resection, outcomesModule primaryOutcomes measure: Overall Survival, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Cancer Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Chen Haiquan, MD, role: CONTACT, phone: +86-21 64175590, phoneExt: 1707, email: hqchen1@yahoo.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06349239, orgStudyIdInfo id: 24Hemato01, briefTitle: Oral Azacitidine Maintenance Post-CPX 351, acronym: ORAZ-351, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-01-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-01-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Nice, class: OTHER, descriptionModule briefSummary: Approximately 10% of patient develop AML after chemotherapy or radiation for unrelated disease (t-AML) and 20% have AML with an antecedent hematologic disorder (AML-MRC). CPX-351 (Vyxeos), a liposomal formulation of a fixed molar ratio (1:5) daunorubicin and cytarabine, has been approved for treatment of adults with newly diagnosed t-AML or AML-MRC. CPX-351 significantly improved median overall survival.Although induction chemotherapy results in remission in many older patients with AML, relapse is common and overall survival is poor. For patients not eligible for HSCT, maintenance therapies are needed to reduce the risk of relapse and prolong overall survival without causing undue adverse effects or compromising health-related quality of life. Oral azacitidine (ONUREG) has been approved by FDA on September, 2020, to treat adult patients with AML who achieved CR or CRi following intensive induction chemotherapy with or without consolidation and who are not able to complete intensive curative therapy (not candidate to HSCT).The use of oral azacitidine maintenance is an integral part of clinical practice for AML patients who have achieved a first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive ""3+7"" induction chemotherapy and who are unable to complete intensive curative therapy.But there are few data on its efficacy as a post-CPX-351 maintenance agent in patients with newly diagnosed t-AML or AML-MRC or de novo AML.THe aim of this study is to show the improvement of overall survival with use of oral Azacitidine as maintenance for patients with de novo AML including t-AML or AML-MRC who achieved complete remission or complete remission with incomplete blood count recovery after CPX-351. Long-term product safety is also being studied, conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: overall survival, secondaryOutcomes measure: Safety and tolerance, eligibilityModule sex: ALL, minimumAge: 64 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU de Nice, status: RECRUITING, city: Nice, country: France, contacts name: CLUZEAU thomas, role: CONTACT, geoPoint lat: 43.70313, lon: 7.26608, hasResults: False
protocolSection identificationModule nctId: NCT06349213, orgStudyIdInfo id: C23-19, secondaryIdInfos id: 2023-A02263-42, type: OTHER, domain: Secondary ID, briefTitle: Uncovering the Cognitive and Neural Mechanisms Underlying Cognitive Time, acronym: TIMES, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-02, primaryCompletionDateStruct date: 2026-11-01, completionDateStruct date: 2030-11-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Institut National de la Santé Et de la Recherche Médicale, France, class: OTHER_GOV, descriptionModule briefSummary: Time processing, the ability to process and encode temporal information, is essential for cognitive functioning and for a large number of daily life activities. In particular, the processing of durations of several seconds is central to cognition, impaired in several pathologies, and has been associated with cognitive changes with advancing age. While behavioral studies have been conducted to specify the neural bases of temporal cognition and their association with other cognitive functions, the mechanisms underlying age-related changes, and individual differences, remain unknown. The project will characterize ageing effects on timing mechanisms and their neural underpinnings. Building on recent advances from neuroscience and age-related cognitive changes, the project focuses on the precision of duration processing, that declines with age, and the associated neural bases. Participants will perform a duration judgement task while (a) electroencephalography, and (b) functional magnetic resonance imaging activity are simultaneously recorded to investigate age effects on structural and functional network connectivity. In addition, striatal dopamine will be measured using a FDOPA PETscan. Evaluation of other temporal cognition processes and general cognition will also be performed. This combination offers a unique opportunity to accurately specifying the neurophysiological underpinning of aging effects on time processing changes. This project will further our understanding of the variability of cognitive performance with advancing age, and contribute to identifying new measures of temporal impairments., conditionsModule conditions: Healthy Aging, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: FDOPA injection before PET imaging, interventions name: Time perception tasks, interventions name: fMRI imaging, interventions name: EEG imaging, interventions name: 3 year follow-up, outcomesModule primaryOutcomes measure: EEG phase lag index differences between group, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349200, orgStudyIdInfo id: 3197, briefTitle: Comparing Binaural Beats and 432Hz Music for Reduction of Preoperative Anxiety in Root Canal Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-27, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-07, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Dow University of Health Sciences, class: OTHER, descriptionModule briefSummary: Many patients suffer from dental anxiety and don't go to dentists for regular checkups. This can lead to the initiation and progression of dental caries, which, if not controlled at the right time, can lead to the loss of the tooth itself. Many forms of distraction have been used to overcome this; music is also one of them. The main objective of this study is to compare the effectiveness of binaural beats and 432 Hz music in reducing preoperative dental unease and anxiety among adult patients undergoing root canal treatment in a dental teaching hospital. The null hypothesis is that both binaural beats and 432 Hz-frequency music are not effective in reducing preoperative dental anxiety among patients undergoing routine endodontic therapy in a dental teaching hospital. A total of three groups will be a part of this study, with a total sample size of 99 participants (33 participants in each group). Group A will listen to 432 Hz music for 10 minutes before the procedure, Group B will listen to binaural beats for 10 minutes before the procedure; and Group C (active control group) will listen to white noise for 10 minutes before the procedure. The Visual Analog Scale for Anxiety will be used to assess the anxiety levels before local anesthesia administration, after local anesthesia administration, and 10 minutes after listening to sounds. Then root canal treatment will be completed as a routine procedure., conditionsModule conditions: Dental Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 99, type: ESTIMATED, armsInterventionsModule interventions name: 432 Hz music, interventions name: Binaural beats, interventions name: White noise, outcomesModule primaryOutcomes measure: Change in Pre-operative Dental Anxiety score using Visual Analog Scale for Anxiety, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Dow University of Health Sciences, status: RECRUITING, city: Karachi, state: Sindh, zip: 74200, country: Pakistan, contacts name: Dr. Hafsa Zaki, role: CONTACT, phone: +923462746052, email: hafsazaki99@hotmail.com, contacts name: Dr. Shahbaz Ahmed, role: CONTACT, phone: +923212000873, email: saj119@googlemail.com, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06349174, orgStudyIdInfo id: 2024-valve-1, briefTitle: Safety and Efficacy of Endobronchial Valve for Bronchoscopic Lung Volume Reduction Surgery: A Prospective Pilot Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-11, primaryCompletionDateStruct date: 2025-03-20, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: China-Japan Friendship Hospital, class: OTHER, descriptionModule briefSummary: The goal of this pliot study al is to preliminarily evaluate the effectiveness and safety of transbronchial lung volume reduction surgery using the self-devloped endobronchial valves for chronic obstructive pulmonary disease patients with emphysema phenotype . The main questions it aims to answer are:Does self-devloped endobronchial valves improve the lung function、exercise capacity and symptons of participants? What surgery-related adverse events do participants have after transbronchial lung volume reduction surgery using the self-devloped endobronchial valves?Participants will:undergo transbronchial lung volume reduction surgery using the self-devloped endobronchial valves.receive follow-up before surgery (baseline) and 3 days, 4 weeks, 12weeks after surgery., conditionsModule conditions: Emphysema, conditions: Chronic Obstructive Pulmonary Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: bronchoscopic lung volume reduction surgery using endobronchial valve, outcomesModule primaryOutcomes measure: Percentage change in FEV1 relative to baseline, secondaryOutcomes measure: Percentage of subjects with FEV1 improvement ≥ 12% after bronchodilators, secondaryOutcomes measure: Percentage change in RV relative to baseline, secondaryOutcomes measure: Percentage change in TLC relative to baseline, secondaryOutcomes measure: Percentage change in DLCO relative to baseline, secondaryOutcomes measure: Percentage change in SGRQ score relative to baseline, secondaryOutcomes measure: Percentage change in mMRC grade relative to baseline, secondaryOutcomes measure: Percentage change in 6MWD relative to baseline, secondaryOutcomes measure: the incidence of surgical-related adverse events, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: China-Japan Friendship Hospital, city: BeiJing, state: Beijing, zip: 100029, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06349161, orgStudyIdInfo id: 1451_02/BVNTW-VNCSKTE, briefTitle: Long-term Outcome of Retroperitoneoscopic One-trocar-assisted Pyeloplasty: A Single-center and Single-surgeon Experience, statusModule overallStatus: COMPLETED, startDateStruct date: 2011-05, primaryCompletionDateStruct date: 2013-06, completionDateStruct date: 2024-03, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: National Children's Hospital, Vietnam, class: OTHER, descriptionModule briefSummary: Open surgical dismembered pyeloplasty has traditionally been the preferred method for treating ureteropelvic junction obstruction (UPJO), with a success rate exceeding 94%. However, it is associated with drawbacks such as increased postoperative pain, extended hospital stays, and visible scarring. Minimally invasive alternatives, including laparoscopic pyeloplasty (LP) and robot-assisted laparoscopic pyeloplasty (RALP), have gained popularity since their introduction in 1993, offering comparable success rates to open surgery while providing cosmetic benefits and shorter hospital stays. Nevertheless, these techniques present challenges in pediatric patients, including limited working space, technical complexities, and prolonged operative times. The retroperitoneoscopic one-trocar-assisted pyeloplasty (OTAP) method, introduced in 2007, combines the advantages of minimally invasive surgery with the success rates of standard dismembered pyeloplasty. Despite favorable outcomes reported by several researchers, comprehensive studies regarding long-term follow-up and clinical outcomes are lacking. This study aims to evaluate the long-term outcomes of OTAP, addressing this gap in the medical literature., conditionsModule conditions: Ureteropelvic Junction Obstruction, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: One-trocar-assisted pyeloplasty, outcomesModule primaryOutcomes measure: Operative time, primaryOutcomes measure: Conversion to open, primaryOutcomes measure: Extension of skin incision, primaryOutcomes measure: Postoperative complications, primaryOutcomes measure: Median length of hospital stays, primaryOutcomes measure: Median follow up length, primaryOutcomes measure: Post-operative mean APD, primaryOutcomes measure: Post-operative mean DRF, primaryOutcomes measure: Mean incision length, primaryOutcomes measure: Recurrence, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 5 Years, stdAges: CHILD, contactsLocationsModule locations facility: The National Hospital of Pediatrics, city: Hanoi, country: Vietnam, geoPoint lat: 21.0245, lon: 105.84117, hasResults: False
protocolSection identificationModule nctId: NCT06349148, orgStudyIdInfo id: NESTLE2022QN-0007, briefTitle: The Effects of Immunonutrition Therapy on Locally Advanced Cervical Cancer Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: SHUANGZHENGJIA, class: OTHER, descriptionModule briefSummary: The goal of this open-label randomized control trial is to study the effect of immunonutrition in locally advanced cervical cancer (LACC) with standard concurrent chemoradiotherapy. LACC patients undergoing radical synchronous chemoradiotherapy will be randomized into the experimental group receiving enteral immunonutrition therapy and the control group receiving standard enteral nutrition support.The main purpose it aims to answer are:1）Can immunonutrition therapy improve patients' dose-limiting toxicity(DLT) and DLT-free survival? 2）Can immunonutrition therapy improve patients' nutritional status and quality of life?, conditionsModule conditions: Cervical Cancers, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: enteral immunonutrition, interventions name: standard oral enteral nutrition, outcomesModule primaryOutcomes measure: Dose-limiting toxicity, primaryOutcomes measure: DLT-free survival, secondaryOutcomes measure: compliance, secondaryOutcomes measure: Prevalence of malnutrition, secondaryOutcomes measure: Prevalence of sarcopenia, secondaryOutcomes measure: QoL (Quality of life), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: laboratory tests, secondaryOutcomes measure: 2-year overall survival, secondaryOutcomes measure: 2-year progression-free survival, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital, Chinese Academy of Medical Sciences, status: RECRUITING, city: Beijing, zip: 100021, country: China, contacts name: SHUANGZHENG JIA, PhD, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06349135, orgStudyIdInfo id: A.Ayman OMFS, briefTitle: Assessment of Serum Concentration of Interleukin-17 and Osteoprotegerin in Response to Surgical Trauma Induced by Management of Mandibular Fractures Via Intraoral Versus Extraoral Approaches: Prospective Cohort Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-04-15, completionDateStruct date: 2025-12-15, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Aya Ayman Ahmed, class: OTHER, descriptionModule briefSummary: Assessment of Serum Concentration of Interleukin-17 and Osteoprotegerin in Response to Surgical Trauma Induced by Management of Mandibular Fractures via Intraoral Versus Extraoral Approaches: Prospective Cohort Study, conditionsModule conditions: Mandibular Fractures, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 2, type: ESTIMATED, armsInterventionsModule interventions name: Open Reduction & Internal Fixation, outcomesModule primaryOutcomes measure: IL-17, primaryOutcomes measure: OPG, secondaryOutcomes measure: Blood Loss, secondaryOutcomes measure: Operative time, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, hasResults: False